Zusammenfassung
40% aller Pleuraergüsse werden durch maligne Tumoren hervorgerufen. Die drei häufigsten Tumoren mit malignen Ergußbildungen sind in absteigender Reihenfolge das Bronchialkarzinom, das Mammakarzinom und die malignen Lymphome. Diese drei Tumorentitäten machen drei Viertel aller malignen Ergüsse aus (Antony et al. 2001). Während maligne Pleuraergüsse bei Männern am häufigsten durch Bronchialkarzinome (49 %) und maligne Lymphome (21 %) verursacht werden (Johnston 1985), treten sie bei Frauen am häufigsten bei Mammakarzinomen (37 %) und gynäkologischen Tumoren (20 %) auf (Tabelle 1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Antony VB, Loddenkemper R, Astoul P (2001) Management of malignant pleural effusions. Eur Respir J 18:402–419
Astoul P, Viallat JR, Laurent JC et al (1991) Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 103:209–213
Fentiman IS, Rubens RD, Hayward IL (1986) A comparison of intracavitary talc and tetracyclin for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol 22:1079–1081
Groth TR, Gatzemeier V, Häussinger K et al (1991) Intrapleural palliative treatment of malignant pleural effusions with mitoxantrone versus placebo (pleural tube alone). Ann Oncol 23:213–215
Gust R, Fabel H (1989) Fibrinkleber-Pleurodese bei rezidivierendem malignen Pleuraerguß. Pneumologie 43:85–87
Hagiwara A, Takahashi T, Lee R et al (1987) Chemotherapy for carcinomatous peritonitis and pleuritis with MMC-CH, mitomycin C adsorbed on activated carbon particles. Cancer 59:245–251
Hatta T, Tsubota N, Yoshimura M, Yanagawa M (1990) Effect of intrapleural administration of minocycline on postoperative air leakage and malignant pleural effussion. Kyobu Geka 43(4):283–6
Hausheer FH, Yarbro JW (1985) Diagnosis and treatment for malignant pleural effusion. Semin Oncol Johnston WW (1985) The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 56:905–909
Keller SM (1993) Current and future therapy for malignant pleural effusion. Chest 103:63–67
Kennedy L, Rusch VW, Strange C et al (1994a) Pleurodesis using talc slurry. Chest 106:342–346
Kennedy L, Sahn SA (1994b) Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 106:1215–1222
Kreuser ED (1992) Pathophysiologie, Häufigkeit und Therapie maligner Pleuraergüsse. Zentralbl Chir 117:91–96
Leverenz A, Heckmayr, Tischer Neuhauss R, Gatzemeier U (2000) Intrapleural palliative treatment of malignant pleural effusions with talcum versus placebo (pleural tube alone). Lung Cancer 29A (suppl 1):274
Little AG, Kadowaki MH, Ferguson MK et al (1988) Pleuro-peritoneal shunting. Ann Surg 208:443–450
Loddenkemper R (1992) Diagnostik der Pleuraergüsse. Aktuelle Diagnos Therapie. Dtsch Med Wochenschr 117:1487–1491
Mansson, T (1988) Treatment of malignant pleural effusion with doxy Scand J Infect Dis [Suppl 53] (29):29–34
Pectasides D, Stewart S, Courtenay-Luck N et al. (1986) Antibody-guided’ tion of malignant pleural and pericardial effusions. Br j Cancer 53:727–731
Perng RP, Chen YM, Wu MF et al (1998) Phase 11 trial of intrapleural pa injection for non-small-cell lung cancer patients with malignant pieural sions. Respir Med 92(3):473–479
Rodriguez-Panadero F, Sandez Gil R, Marin Joan J, Castillo Gomez J (1994) Prediction of results of talc pleurodesis in malignant pleural effusions. Am j Respir Crit Care Med 149:(4,2):All03
Rodriguez-Panadero F, Anatony VB (1997) Pleurodesis: state of the art. Eur Respir J 10:1648–1654
Rosso R, Rimoldi R, Salvati F et al. (1988) Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 45(3):253–256
Ruckdeschel JC, Moores D, Lee JY (1991) Intrapleural therapy for malignant pleural effusions. Chest 100:1528–1535
Sanchez-Armengol A, Rodriguez-Panadero F (1993) Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: Report on 125 cases. Chest 104: 1482–1484
Segalo A Rodriguez-Panadero F, Martin j et al (1994) Trapped lung, pH and outcome of talc pleurodesis in malignant pleural effusion. Eur Respir 1 7 (Suppl 18):270
Shaw P, Agraval R (2004) Pleurodesis for malignant pleural effusions (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK: John Wiley & Sons, Ltd.
Viallat JR, Boutin C, Rey F et al (1993) Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer 71(12):4067–4071
Walker-Renard PB, Vaughan LM, Sahn SA (1994) Chemical pleurodesis for malignant pleural effusion. Arm Intern Med 120:56–64
Yasumoto K, Miyazaki K, Nagkashima A et al (1987) Induction of lymphokineactivated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 47:2184–2187
Zaloznik A, Oswaald S, Langin M (1983) Intrapleural tetracycline in malignant pleural effusions: A randomised study. Cancer 51:752–755
Zimmer PW, Hill M, Casey K et al (1997) Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest 112; 2:430–434
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Deppermann, K.M., Kreuser, E.D. (2006). Intrakavitäre Therapie bei Pleuraerguß. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_66
Download citation
DOI: https://doi.org/10.1007/3-540-31303-6_66
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20657-6
Online ISBN: 978-3-540-31303-8
eBook Packages: Medicine (German Language)